Alport syndrome is a hereditary basement membrane disorder due to mutations within type IV collagen genes. 1, 2 Mutations of the COL4A5 gene encoding the a5-chain of type IV collagen lead to X-linked Alport syndrome (XLAS), whereas mutations of the COL4A4/COL4A3 genes encoding the a3/a4 (IV) chains cause the autosomal recessive form (ARAS) of the disease. 3, 4 Men with XLAS and patients of both genders with homozygous ARAS mutations represent the completely developed pattern of the disease with endstage renal failure during adolescence or early adulthood, including hearing loss and ocular lesions in most of them. 5 In these patients, the course of Alport syndrome has been well studied, including their genotype-phenotype correlations [5] [6] [7] and the beneficial effect of timely nephroprotective therapy. 8 Analysis of heterozygous XLAS carriers in the 'European Community Alport Syndrome Concerted Action' 9 showed a large variability of the clinical course. Hematuria was found in 96% and proteinuria in 75% of the patients; 18% reached end-stage renal failure (59% of them before the age of 40 years). These data showed that the diagnosis of heterozygous COL4A5 mutations is not equivalent to a benign course of disease. The reasons for the large inter-and intrafamilial variability in clinical manifestations in those female patients are only partially known; probably X-inactivation has a pivotal role. 10 Heterozygous COL4A3/COL4A4 mutations result in the phenotype 'familial benign hematuria' or 'thin basement membrane nephropathy' (TBMN). [11] [12] [13] Affected subjects typically present with hematuria. Histologically, TBMN is characterized by a uniformly thinned glomerular basement membrane. Having been regarded as 'benign' familial hematuria for a long time, these patients might have an increased risk to develop severe renal impairment [14] [15] [16] [17] [18] [19] above). TBMN is not a rare disease, as at least 1% of the population is affected; 12, 18 in a series of 76 renal transplant biopsies, even 5.2% of the kidneys presented a thinned glomerular basement membrane. 16 For the first time, the present study compares the risk of renal impairment, end-stage renal disease, and premature death between heterozygous carriers of XLAS and ARAS mutations. In addition, the nephroprotective effect of renin-angiotensin-aldosterone system (RAAS) blockade in patients with heterozygous Alport mutations is evaluated. Figure 1 and Table 1 ).
RESULTS

Founded in
Heterozygous ARAS and XLAS mutations both can lead to renal replacement therapy late in life A total of 41 patients (34 XLAS carriers) reached end-stage renal failure (median age at onset of renal replacement therapy (RRT) 49 years, 95% confidence interval (CI) 59-75 years; 1 male, 40 females; Figure 2 ). Of them, 6 had a nephroprotective RAAS blockade before start of RRT; 11 received a kidney transplant, and 3 of these kidney transplants failed (after 16, 15, and 7.5 years). There are no significant differences in age at onset of RRT between the groups.
Progressive renal failure might affect life expectancy in heterozygous carriers
Life expectancy was evaluated in 213 carriers; 21 of these patients were on RRT (transplanted or dialysis). A total of seven patients died (two transplanted patients, four under dialysis, and one under dialysis, who had undergone transplantation earlier). As this is a relatively small number of events, the median time of survival could not be determined. Therefore, survival is described by the 75% quartile, which is calculated to be 70 (95% CI 67-undetermined years). 'Time on dialysis' was found to affect life expectancy; therefore, end-stage renal disease in Alport carriers seems to increase the risk of premature death ( Figure 3 ; Supplementary Materials S1 and S2 online).
RAAS blockade delays renal failure in heterozygous Alport carriers
A total of 111 patients (47%) received nephroprotective therapy (mean age at onset of therapy 28 years): 109 were treated with angiotensin converting enzyme inhibitors (ACEis), 34 with angiotensin receptor blockers, and 21 with a combination of ACEis and angiotensin receptor blockers (Figures 4 and 5 ). The number of ARAS heterozygotes on therapy was too low for separate analysis in Figure 4 ). Age at onset of RRT in patients having received a nephroprotective therapy before end-stage renal failure differs from untreated patients: onset of RRT occurred significantly later in carriers who were treated with RAAS blockade (Figure 5 ; Po0.0001). Whether this association is causal requires further study. Subgroup analysis revealed a significant effect of RAAS blockade in delaying onset of RRT in XLAS carriers (Po0.0001), as well as in ARAS heterozygotes (P ¼ 0.0231; log-rank test, Supplementary Material S1 online).
DISCUSSION
The aim of the study was to show potential differences in the clinical course of renal damage in heterozygous carriers with either XLAS or ARAS mutations. Further, for the first time, the study investigates the possible impact of a nephroprotective RAAS inhibition in this population.
Our study is in agreement with previous findings in 288 female XLAS carriers with a widespread range of disease severity. The risk of end-stage renal disease was about 30% at the age of 60 years; chronic renal failure appeared in 12%. 9 Forty years before, Gaboardi and co-workers described similar results in 19 Alport families. 20 Similar to previous investigations, 9 our study might as well overestimate the risk of end-stage renal disease in XLAS carriers (as our questionnaires asked for other affected family members). Possible additional risk factors such as hypertension, nephrotoxic medication, or kidney donation 21 might have an important role in aggravation of renal disease. Further studies in animal models for TBMN should focus on these risk factors in order to find new nephroprotective strategies. Although the increased risk for renal failure in XLAS carriers is well established, 9,23 the prognosis of TBMN due to heterozygous ARAS mutations might be worse than formerly supposed. In our study, ARAS and XLAS carriers show no significant differences in the incidences of RRT, proteinuria, and impaired creatinine clearance (Figures 1 and 2) . Microalbuminuria was even more common in ARAS than in XLAS carriers. Age differences between both groups were excluded as a potential confounder (as older patients show a higher incidence of renal damage caused by other reasons such as diabetes, hypertension, atherosclerosis, etc.). ARAS carriers had an even lower mean age than patients with X-linked disease (Table 1) .
Our study design and our questionnaires might have overestimated the risk of end-stage renal disease in TBMN. Patients who have not been recognized as heterozygous carriers were not included in any analysis. However, every single patient with end-stage renal failure due to TBMN still presents a very significant finding, as this is in contrast to the synonym of TBMN: 'familial benign hematuria'. Further, the high prevalence of 1:100 makes TBMN a major source of chronic renal disease in the general population. 11, 12, [16] [17] [18] [19] RAAS blockade significantly delays the onset of end-stage renal failure in proteinuric Alport carriers who received therapy before onset of RRT ( Figure 5 ). This beneficial effect is not caused by a selection bias toward 'better' patients in the treatment group: the number of patients with proteinuria and impaired renal function is even higher in the therapy group (as both medical conditions increase the likelihood of starting therapy; Figure 4) . Because of the low numbers of ARAS heterozygotes on therapy, our study could not analyze XLAS and ARAS groups separately in Figure 4 . For that reason, our results (mostly on heterozygous XLAS) should not be generalized for all ARAS heterozygotes. Further genotype-phenotype analyses in ARAS mutations would be of great use to preemptively provide patients with therapeutic options. However, one can expect a large number of patients with TBMN to remain undiscovered, because their ongoing renal disease is unrecognized (or otherwise explained by 'unknown disease', hypertension, atherosclerosis, or analgetica abuse). Within the next few years, the use of genetic mutation screening will become more common. Thus, TMBN patients can be easily identified, which poses the possibility to start nephroprotective therapy earlier. According to our study, widespread preemptive RAAS blockade in TBMN patients with microalbuminuria, proteinuria, or high blood pressure could prevent a large number of severe impairments of renal function and even dialysis.
Heterozygous carriers of XLAS and ARAS mutations both show an impaired life expectancy when reaching RRT. Preventive RAAS blockade might prolong life and improve quality of life in these carriers. The relatively high risk of endstage renal disease and the impaired life expectancy of Alport carriers on RRT should lead to a greater alertness toward patients with TBMN presenting the non-benign symptoms of familial benign hematuria. The term 'familial benign hematuria' is misleading and has an underlying renal disease that can affect quality of life and life expectancy. As these patients reflect 1% of the total population, the sometimes non-benign course of TBMN and XLAS carriers is relevant to nephrologists. Yearly follow-up by a nephrologist and earlyon nephroprotective RAAS blockade should be advised for all newly diagnosed TBMN patients with microalbuminuria, proteinuria, or high blood pressure, and heterozygous XLAS carriers.
MATERIALS AND METHODS Inclusion and exclusion criteria
The diagnosis of the heterozygous status was proven by (1) mutation analysis or (2) kidney biopsy plus genetic consultation for decision in between XLAS or ARAS inheritance (including a conclusive genealogic tree and/or linkage analysis). Patients were excluded if they were affected males with XLAS or patients with genetically proven homozygous ARAS. Patients were excluded if they did not give informed consent or the diagnosis was suspected but not confirmed or if they donated a kidney (living donor to affected family member).
Primary data collection, assignment, and follow-up The Registry retraces data on several decades in three generations of Alport syndrome patients, hindering a prospective study design. In all, 310 centers participated in the European Alport Registry over the years. Data were hosted centrally on a non-open access computer and were anonymized at the University of Göttingen, Germany. Questionnaires included demographic data (age, gender, country of origin, family history, mode of inheritance), clinical and laboratory data (how the diagnosis was made, age at onset of RRT, ACEi therapy, and age at onset of therapy, renal parameters before and after onset of ACEi therapy such as proteinuria, creatinine, creatinine clearance, cholesterol, hypertension, hearing loss, eye symptoms, death from all causes, and side effects of medications such as hyperkalemia, angioedema, renal failure, cough, hypotension, rhabdomyolysis, and others). Data were updated via telephone interviews, email, facsimile, or by personal contact with both physicians and patients. The registry and data storage conform with good clinical practice guidelines, and were approved by the Ethics Committee (AZ 10/11/ 06; French data by the Commission Nationale de l'Informatique et des Libertés #908249). Data were collected from Germany, France, Spain, Belgium, Austria, Switzerland, United States of America (limited to only those families recently moved from Europe to USA), Russia, Serbia, Romania, Italy, and Turkey. The primary data set was updated exclusively in spring 2010 by the lead investigator to ensure compliance to the Ethics Committee recommendations. Data were updated within 12 months of the analysis date in 86% of cases. Of 393 (2%) patients or carriers, 8 were lost to follow-up.
Outcome measures and intervention
The study end points were 'RRT', 'age at onset of RRT', 'impaired renal function' (creatinine-clearance below 60 ml/min), 'proteinuria' (proteinuria 4300 mg/day), and 'age at death'. Owing to the genetic defect in Alport carriers at birth, life expectancy was defined as life span from birth to death. Impaired creatinine clearance was defined as o60 ml/min in a 24-h urine collection. Proteinuria was defined as 4300 mg protein per day, and microalbuminuria as 30-300 mg protein per day in a 24-h urine collection. The study explored the treatment effects of ACEis and angiotensin receptor blockers; the control intervention was with out therapy. The most commonly used ACEis were Ramipril (0.025-0.1 mg/kg body weight) and Enalapril (0.125-1.0 mg/kg body weight).
Statistical analysis
Distributions of continuous variables are summarized by means, whereas frequencies and percentages are given for categorical (including binary) variables. The efficacy end points 'age at onset of RRT' and 'age at death' are censored in some patients, as not all patients included in the analyses have started RRT (or died). Therefore, appropriate statistical methods for censored time-toevent data were used, including the Kaplan-Meier estimator and the log-rank test. 24 Median event times are reported with 95% CIs, which are based on log-log transformed CIs of the event probabilities. If the CIs of the event probabilities are too wide across all observed times because of the small sample size, the confidence limits for the median cannot be determined. All analyses are of an exploratory nature and therefore no correction for multiple testing was applied. All reported P-values are two-sided, and those smaller than 0.05 are referred to as statistically significant. All inferential analyses were carried out using SAS version 9.2.
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